Collaborative virtual screening to elaborate an imidazo[1,2-a]pyridine hit series for visceral leishmaniasis-Reference-Cited by-同舟云学术

Collaborative virtual screening to elaborate an imidazo[1,2-a]pyridine hit series for visceral leishmaniasis

Published:2021 Issue:3 Volume:12 Page:384-393
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Akao Yuichiro¹²³,Canan Stacie⁴⁵⁶⁷,Cao Yafeng⁸⁹¹⁰,Condroski Kevin⁴⁵⁶⁷,Engkvist Ola¹¹¹²¹³^ORCID,Itono Sachiko¹²³,Kaki Rina¹⁴¹⁵³,Kimura Chiaki¹⁴¹⁵³,Kogej Thierry¹¹¹²¹³,Nagaoka Kazuya¹⁶¹⁷³,Naito Akira¹⁴¹⁵³,Nakai Hiromi¹⁴¹⁵³,Pairaudeau Garry¹⁸¹⁹²⁰,Radu Constantin²¹²²²³,Roberts Ieuan¹⁸¹⁹²⁰,Shimada Mitsuyuki¹²³,Shum David²¹²²²³,Watanabe Nao-aki¹⁶¹⁷³,Xie Huanxu⁸⁹¹⁰,Yonezawa Shuji¹⁴¹⁵³,Yoshida Osamu¹⁴¹⁵³,Yoshida Ryu¹⁴¹⁵³,Mowbray Charles²⁴²⁵²⁶,Perry Benjamin²⁴²⁵²⁶^ORCID

Affiliation:

1. Takeda Pharmaceutical Company Limited

2. Fujisawa

3. Japan

4. Celgene Corporation

5. Celgene Global Health

6. San Diego

7. USA

8. WuXi AppTec Company Ltd.

9. Wuhan 430075

10. People's Republic of China

11. AstraZeneca Discovery Sciences, R&D

12. Gothenburg

13. Sweden

14. Shionogi & Co., Ltd

15. Toyonaka-shi

16. Eisai Co., Ltd

17. Tsukuba

18. AstraZeneca, Discovery Sciences, R&D

19. Cambridge

20. UK

21. Institut Pasteur Korea

22. Seongnam-si

23. 13488 Republic of Korea

24. Drugs for Neglected Diseases initiative

25. Geneva 1202

26. Switzerland

Abstract

Ligand-based similarity screening of proprietary pharmaceutical company libraries enables rapid hit to lead investigation of a chemotype with anti-leishmania activity.

Funder

Global Health Innovative Technology Fund

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2021/MD/D0MD00353K

Reference33 articles.

1. Leishmaniasis

2. Leishmaniasis and poverty

3. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015